Ret Proto-Oncogene anticorps (AA 1012-1042)

N° du produit ABIN3032460

Détail du produit anti-Ret Proto-Oncogene anticorps

Antigène: Ret Proto-Oncogene (RET)

Épitope: AA 1012-1042

Reactivité: Humain

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp Ret Proto-Oncogene est non-conjugé

Application: Western Blotting (WB), ELISA, Immunohistochemistry (IHC)

Purification: Purified

Immunogène: A portion of amino acids 1012-1042 from the human protein was used as the immunogen for this RET antibody.

Isotype: Ig Fraction

Information d'application

Indications d'application: Titration of the RET antibody may be required due to differences in protocols and secondary/substrate sensitivity.\. Western blot: 1:1000,IHC (Paraffin): 1:50-1:100

Restrictions: For Research Use only

Stockage

Format: Liquid

Buffer: In 1X PBS, pH 7.4, with 0.09 % sodium azide

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: -20 °C

Stockage commentaire: Aliquot the RET antibody and store frozen at -20°C or colder. Avoid repeated freeze-thaw cycles.

Détails sur Ret Proto-Oncogene

Antigène: Ret Proto-Oncogene (RET)

Autre désignation: RET (RET Produits)

Synonymes: anticorps c-ret, anticorps cret, anticorps etID315074.13, anticorps ret1, anticorps wu:fd13h01, anticorps X-ret, anticorps ret-A, anticorps xret, anticorps RET, anticorps MTC1, anticorps CDHF12, anticorps CDHR16, anticorps HSCR1, anticorps MEN2A, anticorps MEN2B, anticorps PTC, anticorps RET-ELE1, anticorps RET51, anticorps RET9, anticorps c-Ret, anticorps ret proto-oncogene receptor tyrosine kinase, anticorps ret proto-oncogene S homeolog, anticorps ret proto-oncogene, anticorps ret, anticorps ret.S, anticorps RET, anticorps Ret

Sujet: RET, a member of the cadherin superfamily, is one of the receptor tyrosine kinases, which are cell-surface molecules that transduce signals for cell growth and differentiation. This protein plays a crucial role in neural crest development, and the gene can undergo oncogenic activation in vivo and in vitro by cytogenetic rearrangement. Mutations i are associated with the disorders multiple endocrine neoplasia, type IIA, multiple endocrine neoplasia, type IIB, Hirschsprung disease, and medullary thyroid carcinoma.

UniProt: P07949

Pathways: Signalisation RTK, Dopaminergic Neurogenesis, Regulation of Cell Size, Tube Formation